Table 3.

Currently approved clinical trials using ADAM17 inhibitors for tumor treatment.

Diseases	ADAM17 inhibitors	Phase for trial	Trial ID	First Posted date	Recruitment Status	Last Update Posted
Diffuse Large B Cell Non-Hodgkin Lymphoma	INCB7839 + Rituximab	Phase I/II	NCT02141451	May 19, 2014	Completed	Feb 19, 2020
Gliomas	INCB7839	Phase I	NCT04295759	Mar 4, 2020	Active, not recruiting	Aug 16, 2022
Breast Cancer	INCB007839 + Trastuzumab and Vinorelbine	Phase I/II	NCT01254136	Dec 6, 2010	Terminated	Jan 25, 2012
Breast Cancer	INCB007839 + trastuzumab and docetaxel	Phase I/II	NCT00864175	Mar 18, 2009	Terminated	Jan 18, 2018
Solid Tumors and Hematologic Malignancy	INCB007839	Phase I	NCT00820560	Jan 12, 2009	Completed	Jan17, 2018

(Source: the U.S. National Library of Medicine, https://clinicaltrials.gov/).